Literature DB >> 22041344

Admission glucose level and in-hospital outcomes in diabetic and non-diabetic patients with ST-elevation acute myocardial infarction.

Dong-bao Li1, Qi Hua, Jincheng Guo, Hong-wei Li, Hui Chen, Shu-mei Zhao.   

Abstract

BACKGROUND: Hyperglycemia on admission is a predictor of an unfavorable prognosis in patients with ST-elevation Acute Myocardial Infarction (AMI). Data concerning associations between an elevated glucose level on admission and other in-hospital complications are still limited.
METHODS: A total of 1,137 AMI patients with complete admission blood glucose level (ABGL) analysis were identified and stratified according to ABGL.
RESULTS: A total of 16.1% patients had admission glucose level <5 mmol/L, 36.1% <7 mmol/L, 20.2% <9 mmol/L, 9.9% <11 mmol/L and 17.7% ≥11 mmol/L. Compared with the euglycemia group, both the hypo- and hyperglycemia groups were associated with higher in-hospital mortality. In-hospital mortality of diabetic patients with hypoglycemia (12.2%) was higher than that of diabetic patients with either euglycemia or mild hyperglycemia (11.1%, or 10.7% relatively). The same results were seen in non-diabetic patients. In the logistic regression analysis, admission glucose and cardiac function of Killip grade were the independent predictors of in-hospital death for patients with AMI.
CONCLUSION: Elevated admission glucose levels are associated with an increased risk of life-threatening complications in diabetic and non-diabetic AMI patients. Compared with the euglycemia group, hypoglycemia was associated with a higher trend of in-hospital mortality.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22041344     DOI: 10.2169/internalmedicine.50.5750

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  8 in total

Review 1.  Inpatient Continuous Glucose Monitoring and Glycemic Outcomes.

Authors:  David L Levitt; Kristi D Silver; Elias K Spanakis
Journal:  J Diabetes Sci Technol       Date:  2017-03-14

2.  Using a Diabetes Risk Score to Identify Patients Without Diabetes at Risk for New Hyperglycemia in the Hospital.

Authors:  Carlos E Mendez; Rebekah J Walker; Aprill Z Dawson; Kevin Lu; Leonard E Egede
Journal:  Endocr Pract       Date:  2021-04-19       Impact factor: 3.701

3.  Increased glycemic variability is independently associated with length of stay and mortality in noncritically ill hospitalized patients.

Authors:  Carlos E Mendez; Ki-Tae Mok; Ashar Ata; Robert J Tanenberg; Jorge Calles-Escandon; Guillermo E Umpierrez
Journal:  Diabetes Care       Date:  2013-10-29       Impact factor: 19.112

4.  Admission Glucose and In-hospital Mortality after Acute Myocardial Infarction in Patients with or without Diabetes: A Cross-sectional Study.

Authors:  Shi Zhao; Karthik Murugiah; Na Li; Xi Li; Zi-Hui Xu; Jing Li; Chen Cheng; Hong Mao; Nicholas S Downing; Harlan M Krumholz; Li-Xin Jiang
Journal:  Chin Med J (Engl)       Date:  2017-04-05       Impact factor: 2.628

5.  Admission hyperglycemia and adverse outcomes in diabetic and non-diabetic patients with non-ST-elevation myocardial infarction undergoing percutaneous coronary intervention.

Authors:  Yuanyuan Hao; Qun Lu; Tao Li; Guodong Yang; Peijing Hu; Aiqun Ma
Journal:  BMC Cardiovasc Disord       Date:  2017-01-05       Impact factor: 2.298

6.  Association of Admission Blood Glucose Level with Major Adverse Cardiac Events in Acute Coronary Syndrome; a Cohort Study.

Authors:  Mostafa Alavi-Moghaddam; Mohamad Parsa-Mahjoob; Robabeh Ghodssi-Ghassemabadi; Bita Bitazar
Journal:  Arch Acad Emerg Med       Date:  2019-04-16

7.  High admission glucose levels predict worse short-term clinical outcome in non-diabetic patients with acute myocardial infraction: a retrospective observational study.

Authors:  Xiao Song Ding; Shan Shan Wu; Hui Chen; Xue Qiao Zhao; Hong Wei Li
Journal:  BMC Cardiovasc Disord       Date:  2019-07-04       Impact factor: 2.298

Review 8.  Machine Learning Models for Inpatient Glucose Prediction.

Authors:  Andrew Zale; Nestoras Mathioudakis
Journal:  Curr Diab Rep       Date:  2022-06-27       Impact factor: 5.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.